Astellas Pharma Gmbh

Meiji Seika Pharma Co., Ltd.

Maiko Iida

Hiroshi Shibata

Yuji Koga

Kenichi Onda

Itsuro Shimada

Tsubasa Watanabe

Ippei Sato

Yuji Tabata

Kazuhiko Ohne

Kyoichi Maeno

Hisao Hamaguchi

Yutaka Kondoh

Kenichiro Imamura

Yoshimasa Imamura

Takeshi Hanazawa

Eisuke Nozawa

Takahiro Matsuya

Hiroki Fukudome

Shigetoshi Kikuchi

Nobuaki Shindou

Kaori Kaneda

Sho Takahata

Makoto Ohyama

Yukihiro Takemoto

Hideki Sakagami

An excellent drug for treating or preventing cardiovascular diseases, based on cGMP production enhancing action due to soluble guanylate cyclase activating action, is provided. It was found that imidazopyridine compounds having a carbamoyl group at the 3-position and a substituent bonded at the 8-position via an oxygen atom in an imidazo[1,2-a]pyridine skeleton exhibits a cGMP production enhancing action by a potent soluble guanylate cyclase activating action, and is useful as a drug for treating or preventing various soluble guanylate cyclase-related cardiovascular diseases, thereby completing the present invention.

Imidazopyridine compounds

Compounds of formula (I): in which the variables are defined herein, are useful for the treatment of cancer in patients which express the EGFR T790M mutation.

Pyrazinecarboxamide compound

An anti-fungal agent for tinea comprising as active ingredient a compound having the skeleton of 2-(1H-pyrazol-1-yl)phenol represented by the following formula (I) or (II) or a salt thereof is provided 

Topical antifungal agent

Growing community of inventors

Tokyo, Japan

Maiko Iida